• Clinical Insights: August 4, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Monjuvi® (tafasitamab-cxix) Injection – New Drug Approval – July 31, 2020 – MorphoSys AG announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix) in… Read more »

  • Clinical Insights: July 28, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval TecartusTM (brexucabtagene autoleucel) – New Drug Approval – July 24, 2020 – Kite, a Gilead Company announced that the U.S. Food and Drug Administration (FDA) has granted accelerated… Read more »

  • Clinical Insights: July 21, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval  No new update. New Formulation Approval No new update. New Indication Approval Botox® (onabotulinumtoxinA) – New Expanded Indication Approval – July 9, 2020 – Allergan, an AbbVie company,… Read more »

  • Clinical Insights: July 14, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval  UpneeqTM (oxymetazoline hydrochloride) Ophthalmic Solution – New Drug Approval – July 8, 2020 – Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, announced that the U.S. Food and… Read more »

  • Clinical Insights: July 7, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval  ByfavoTM (remimazolam) Injection – New Drug Approval – July 2, 2020 – Cosmo Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Byfavo™ (remimazolam injection)… Read more »

  • Clinical Insights: June 30, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Fintepla® (fenfluramine) Oral Solution – New Drug Approval – June 26, 2020 – The U.S. Food and Drug Administration approved Fintepla® (fenfluramine), a Schedule IV controlled substance, for… Read more »

  • Clinical Insights: June 23, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval  GimotiTM (metoclopramide) Nasal Spray – New Drug Approval – June 19, 2020 – Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, announced… Read more »

  • Clinical Insights: June 16, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval  ZepzelcaTM (lurbinectedin) Injection – New Drug Approval – June 15, 2020 – PharmaMar announced, along with Jazz Pharmaceuticals plc, that the U.S. Food and Drug Administration (FDA) has… Read more »

  • Clinical Insights: June 9, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval No new update. New Formulation Approval No new update. New Indication Approval RecarbrioTM (imipenem-cilastatin and relebactam) Injection – New Drug Indication Approval – June 4, 2020 –… Read more »

  • Clinical Insights: June 2, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval OriahnnTM (elagolix/estradiol/norethindrone acetate and elagolix) Capsules – New Drug Approval – May 29, 2020 – The U.S. Food and Drug Administration granted approval to OriahnnTM (an estrogen and… Read more »